Literature DB >> 3377810

Characteristics of iron(III) uptake by isolated fragments of rat small intestine in the presence of the hydroxypyrones, maltol and ethyl maltol.

J A Levey1, M A Barrand, B A Callingham, R C Hider.   

Abstract

Accumulation of radioactive iron (59Fe) into isolated fragments of rat small intestine in the presence of two hydroxypyrones, maltol and ethyl maltol, was compared with that in the presence of another chelator of iron(III), nitrilotriacetic acid (NTA). The characteristics of uptake were similar with all three ligands. Between 10(-6) and 10(-4) M, iron uptake showed saturable kinetics. The uptake was partially inhibited by metabolic inhibitors. Above 10(-4) M a non-saturable uptake, unaffected by metabolic inhibitors became evident in the presence of the pyrones. The distribution of 59Fe after uptake was determined by gel filtration. At low iron concentrations (10(-6) M), 35-40% of absorbed iron was associated with proteins of molecular weights similar to those of ferritin and transferrin. At high concentrations (10(-3) M), the majority of 59Fe was found in a low molecular weight fraction. At each concentration, a small amount of 59Fe was bound to a membrane fraction. 5% Polyethylene glycol, which reduces glycocalyx viscosity enhanced uptake at low iron concentrations (10(-6) M) but did not affect the non-saturable diffusion seen at higher concentrations (10(-3) M). The iron(II) chelator, bathophenanthroline sulphonate (10(-3) M), decreased uptake at low iron concentrations but did not affect the non-saturable uptake. It is suggested that conversion of iron(III) to iron(II) may take place at the mucosal cell surface before uptake via the saturable system. Apparent Km values for iron uptake via the saturable system were higher in the presence of maltol and ethyl maltol than in the presence of NTA, presumably since the iron binds more avidly to the hydroxypyrones and so is less readily donated. Excess ligand, either pyrone or NTA, reduced the rate at which 59Fe was donated to the uptake system. The Vmax value for uptake from the pyrones was greater than from NTA. It is concluded that maltol, ethyl maltol and NTA can hold iron(III) in solution and donate it to an endogenous uptake system. But, the hydroxypyrones may be more suitable ligands for the oral administration of iron since, when complexed with iron, they lack the toxic effects associated with iron(III)-NTA and with iron(II) preparations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3377810     DOI: 10.1016/0006-2952(88)90556-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.

Authors:  Bernd Bokemeyer; Annette Krummenerl; Christian Maaser; Stefanie Howaldt; Michael Mroß; Nick Mallard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

2.  Evidence for regulatory control of iron uptake from ferric maltol across the small intestine of the rat.

Authors:  M A Barrand; B A Callingham
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

3.  Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat.

Authors:  M A Barrand; B A Callingham; P Dobbin; R C Hider
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

4.  Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.

Authors:  Christoph Gasche; Tariq Ahmad; Zsolt Tulassay; Daniel C Baumgart; Bernd Bokemeyer; Carsten Büning; Stefanie Howaldt; Andreas Stallmach
Journal:  Inflamm Bowel Dis       Date:  2015-03       Impact factor: 5.325

5.  Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.

Authors:  C Schmidt; T Ahmad; Z Tulassay; D C Baumgart; B Bokemeyer; S Howaldt; A Stallmach; C Büning
Journal:  Aliment Pharmacol Ther       Date:  2016-05-29       Impact factor: 8.171

Review 6.  Diagnosis and treatment of anemia in patients with inflammatory bowel disease.

Authors:  Victoria Mücke; Marcus M Mücke; Tim Raine; Dominik Bettenworth
Journal:  Ann Gastroenterol       Date:  2016-09-06

7.  Vaper, Beware: The Unique Toxicological Profile of Electronic Cigarettes.

Authors:  Silke Schmidt
Journal:  Environ Health Perspect       Date:  2020-05-04       Impact factor: 9.031

8.  Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.

Authors:  Stefanie Howaldt; Eugeni Domènech; Nicholas Martinez; Carsten Schmidt; Bernd Bokemeyer
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 5.325

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.